Nemunaitis J, Singer J W
Department of Veterans Affairs Medical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Am J Clin Oncol. 1991;14 Suppl 1:S15-8. doi: 10.1097/00000421-199112001-00004.
To examine the effects of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients undergoing autologous bone marrow transplantation (ABMT), a series of phase I, II, and III trials was done. rhGM-CSF was given to patients undergoing ABMT for lymphoid neoplasia beginning 2 h after marrow infusion. The results indicate that rhGM-CSF is well tolerated and stimulates early neutrophil and platelet recovery. rhGM-CSF did not affect relapse or survival. Patients who received rhGM-CSF had fewer infections, less marrow transplant-related toxicity, and shorter hospital stays than control patients.
为研究重组人粒细胞巨噬细胞集落刺激因子（rhGM-CSF）对接受自体骨髓移植（ABMT）患者的影响，开展了一系列Ⅰ期、Ⅱ期和Ⅲ期试验。对于因淋巴瘤接受ABMT的患者，在骨髓输注后2小时开始给予rhGM-CSF。结果表明，rhGM-CSF耐受性良好，可促进中性粒细胞和血小板早期恢复。rhGM-CSF不影响复发或生存率。与对照组患者相比，接受rhGM-CSF的患者感染较少，与骨髓移植相关的毒性较小，住院时间较短。
